Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Therapeutic agent for polycythemia

A polycythemia, antibody technology, applied in extracellular fluid diseases, drug combinations, anti-receptor/cell surface antigen/cell surface determinant immunoglobulin, etc., can solve problems such as low satisfaction and lower QOL of patients

Pending Publication Date: 2022-04-15
PERSEUS PROTEOMICS INC +1
View PDF20 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, these treatments have side effects such as iron deficiency, bone marrow suppression, etc., which reduce the QOL of patients
Since satisfaction with existing treatment methods is low, treatment methods with fewer side effects and improved QOL of patients are desired

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Therapeutic agent for polycythemia
  • Therapeutic agent for polycythemia
  • Therapeutic agent for polycythemia

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0111] Example 1: Identification of the binding site of the TfR436 antibody

[0112] The TfR436 antibody does not cross-react with mouse TfR, but shows cross-reactivity with hamster TfR. The amino acid sequences of the transferrin (TF) binding site (amino acids 569-760) in TfR were compared. Amino acids in the human TfR sequence identical to those of hamster but different from those of mouse were selected. Such as figure 1 The selected amino acids were subjected to point mutations as shown to prepare soluble TfR mutant fragments (TfR mutant fragments). (1) Preparation of soluble wild type TfR (wild type TfR, sTfR) and TfR mutant fragment (TfR mutant fragment) (MF1-MF7)

[0113] Fully synthetically encoded human TfR extracellular region (amino acids 89-760) or figure 1 The nucleotide sequences of the respective TfR mutant fragments (MF1 to MF7) and AAARGGPEQKLISEE DLNSAVDHHHHHH (SEQ ID NO: 10) are shown. The neomycin resistance gene and the DHFR gene were introduced into t...

Embodiment 2

[0117] Example 2: Comparison of Tf-TfR Binding Inhibition of TfR436 Antibody and Comparative Antibody

[0118] (1) Production of comparative antibody A24

[0119] The A24 antibody against TfR is described in the patent document US2008 / 0193453. In order to compare the TfR436 antibody with this antibody, the deposited hybridoma (Hybridoma) was obtained to produce the antibody. Specifically, hybridomas were added to RPMI1640 (GIBCO), FBS 10% medium so that the cell concentration became 1-2×10 5 / mL at 37°C in 5% CO 2 Cultivate in an incubator. After the expanded culture, the cells were recovered by centrifugation, washed twice with PBS, and further expanded to 550 mL in a serum-free medium cosmedium005 (Cosmobio) and 0.5% Nutridoma-CS (Roche). Five days after the cells became confluent, the culture supernatant was recovered by centrifugation.

[0120] The recovered supernatant was loaded on the protein A carrier (Ab-Capcher ExTra: Protenova Company), and the antibody bound t...

Embodiment 3

[0124] Example 3: EPO-independent nucleated erythroid differentiation inhibitory effect of hematopoietic stem cells derived from PV patients

[0125] Hematopoietic stem cells derived from PV patients are characterized by the ability to form BFU-E and CFU-E in the absence of erythropoietin (EPO). The inhibitory activity of TfR436 on the colony formation of these cells was investigated.

[0126] (1) PBMC separation

[0127] With regard to the peripheral blood of PV patients after bloodletting, 20 mL of peripheral blood was respectively injected into three 50 mL centrifuge tubes, and an equal amount of PBS (Gibco) was added and mixed. Inject LymphoSep and lymphocyte separation medium (Lymphocyte Separation Media, MP Biomedicals TM ) 15 mL, slowly added 30 mL each of peripheral blood diluted with PBS, and centrifuged at 1,500 rpm for 30 minutes at room temperature. After centrifugation, the plasma in the supernatant was removed, and the PBMC layer was collected with a pipette a...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The technical problem to be solved by the invention is to provide the medicine for treating the polycythemia. The present invention makes it possible to provide a therapeutic agent for polycythemia, said therapeutic agent containing an antibody that recognizes amino acids at positions 629th to 633rd of a human transferrin receptor.

Description

technical field [0001] The present invention relates to a drug for treating polycythemia containing anti-transferrin receptor antibody. Background technique [0002] Transferrin receptor (TfR) is a Type II membrane protein expressed on the cell surface. TfR transports iron into the cell by binding to the ligand transferrin to maintain cell survival and division. TfR is low expressed in most normal cells, but it has been reported to be expressed in some cells such as skin epidermal basal cells and intestinal epithelial cells (Non-Patent Documents 1 to 3). In nucleated erythrocytes and placental trophoblasts, TfR is highly expressed due to the high requirement for iron intake (Non-Patent Documents 4 and 5). [0003] Polycythemia Vera (PV) is a chronic myeloid proliferative tumor characterized by an excessive increase in red blood cells. Examples of clinical manifestations of PV include increased blood viscosity due to an increase in red blood cells in the blood, decreased b...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07K16/28C07K16/46A61K39/395A61P7/00A61K31/17
CPCA61P7/00C07K16/2881C07K2317/33C07K2317/34C07K2317/76C07K2317/92A61K31/17A61K39/3955A61K2039/505A61K2300/00A61P35/00A61K45/06
Inventor 张黎临野村富美子小松则夫荒木真理人
Owner PERSEUS PROTEOMICS INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com